Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma
dc.contributor.author | Di Nunno, Vincenzo | |
dc.contributor.author | Massari, Francesco | |
dc.contributor.author | Mollica, Veronica | |
dc.contributor.author | Cimadamore, Alessia | |
dc.contributor.author | Santoni, Matteo | |
dc.contributor.author | Cheng, Liang | |
dc.contributor.author | Lopez-Beltran, Antonio | |
dc.contributor.author | Scarpelli, Marina | |
dc.contributor.author | Montironi, Rodolfo | |
dc.contributor.department | Pathology and Laboratory Medicine, School of Medicine | en_US |
dc.date.accessioned | 2020-02-24T13:57:42Z | |
dc.date.available | 2020-02-24T13:57:42Z | |
dc.date.issued | 2019-07 | |
dc.eprint.version | Final published version | en_US |
dc.identifier.citation | Di Nunno, V., Massari, F., Mollica, V., Cimadamore, A., Santoni, M., Cheng, L., Lopez-Beltran, A., Scarpelli, M., & Montironi, R. (2019). Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma. Annals of translational medicine, 7(Suppl 3), S137. https://doi.org/10.21037/atm.2019.06.06 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/22114 | |
dc.language.iso | en_US | en_US |
dc.publisher | AME Publishing Company | en_US |
dc.relation.isversionof | 10.21037/atm.2019.06.06 | en_US |
dc.relation.journal | Annals of Translational Medicine | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | PMC | en_US |
dc.subject | Non-Clear Cell Renal Cell Carcinoma | en_US |
dc.subject | Uncommon Diagnoses | en_US |
dc.subject | Interventional studies | en_US |
dc.subject | Cabozantinib | en_US |
dc.subject | Tyrosine Kinase Inhibitor | en_US |
dc.subject | Immunotherapy | en_US |
dc.title | Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma | en_US |
dc.type | Article | en_US |
ul.alternative.fulltext | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685836/ | en_US |